Core Points - Harrow, a leading North American eyecare pharmaceutical company, will report its financial results for Q2 2025 on August 11, 2025, after market close [1] - A conference call and live webcast will be held on August 12, 2025, at 8:00 a.m. Eastern Time to discuss the results and provide a business update [1] - The second quarter Letter to Stockholders will be available on Harrow's website [1] Conference Call Information - Participants can access the live webcast on the "Investors" page of Harrow's website, with a replay available for one year [2] - Telephone participants must register in advance to receive a unique dial-in number and PIN for the call [2] Company Overview - Harrow, Inc. is focused on the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market [3] - The company aims to make its pharmaceutical products accessible and affordable to millions of patients each year [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - Harrow reported Q1 2025 revenue of $47.8 million, which was below the consensus estimate of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [3]

Core Viewpoint - The Schall Law Firm is investigating Harrow, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - Harrow, Inc. reported Q1 2025 financial results on May 8, 2025, with revenues that fell short of consensus estimates and an adjusted EBITDA of -$1.9 million [2]. - Following the announcement of these results, Harrow's shares experienced a decline of over 4% [2].

Company Overview - Harrow (HROW) shares increased by 11.4% to close at $34.93, supported by high trading volume, contrasting with a 0.7% gain over the past four weeks [1] - The rise in share price is linked to positive investor sentiment regarding the sales growth of its ophthalmic pharmaceutical products in North America, which is anticipated to enhance shareholder value [1] Earnings Expectations - Harrow is projected to report quarterly earnings of $0.01 per share, reflecting a year-over-year increase of 107.7% [2] - Expected revenues for the upcoming quarter are $65.83 million, representing a 34.5% increase from the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Harrow has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [3] - Harrow holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Comparison - Harrow operates within the Zacks Medical - Drugs industry, where another company, electroCore, Inc. (ECOR), experienced an 8.9% decline in its stock price, closing at $6.88 [3] - electroCore's consensus EPS estimate has also remained unchanged at -$0.32, showing a year-over-year change of 15.8% [4]

Group 1 - The core focus of Quad 7 Capital is to provide investment opportunities through their BAD BEAT Investing platform, emphasizing both long and short trades [1] - The team consists of 7 analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, aiming to educate investors on proficient trading [1] - Since May 2020, the company has maintained an average position of 95% long and 5% short, showcasing a strategic approach to market conditions [1] Group 2 - BAD BEAT Investing offers various benefits, including weekly well-researched trade ideas, access to multiple chat rooms, and daily summaries of key analyst upgrades and downgrades [2] - The platform also provides education on basic options trading and extensive trading tools to enhance investor knowledge and skills [2]

Core Viewpoint - Harrow, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in its stock price [1][2]. Financial Performance - Harrow reported revenue of $47.8 million for Q1 2025, which was below the consensus estimate of $57.0 million [2]. - The company also reported an adjusted EBITDA of -$1.9 million, missing the expected $11.9 million [2]. - Following the announcement of these results, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on May 8, 2025 [2]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Harrow investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Harrow reported first-quarter 2025 revenue of $47.8 million, which missed consensus estimates of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, falling short of the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on the same day [3]

Group 1 - Golf is a unique sport focused on overcoming the course rather than competing against other players, emphasizing the importance of environmental factors [1] Group 2 - The company promotes a portfolio strategy that generates income without the need for selling assets, aiming to simplify retirement investing [3] - The Income Method offered by the company targets a yield of 9-10%, appealing to investors seeking strong returns [3] - A promotional offer is available for joining the investment group at a price of $599, highlighting urgency due to rising prices [3]

Core Insights - Harrow has acquired exclusive U.S. commercial rights for BYQLOVI™, a new ophthalmic steroid approved by the FDA for post-operative inflammation and pain, marking a significant advancement in the eyecare pharmaceutical market [1][2] Company Overview - Harrow is a leading North American eyecare pharmaceutical company focused on innovative ophthalmic products, aiming to enhance patient access and outcomes [16] - Formosa Pharmaceuticals is a clinical stage biotechnology company specializing in ophthalmology and oncology, utilizing proprietary nanoparticle formulation technology to improve drug delivery [15] Product Details - BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% is indicated for treating post-operative inflammation and pain following ocular surgery [5] - The product is expected to be available in the U.S. market in the fourth quarter of 2025 [1] Clinical Efficacy - Clinical studies show that 77% to 85% of patients reported no pain at Day 4 post-surgery, and 82% to 87% reported no pain at Day 8 post-surgery, indicating strong pain relief [3] - Inflammation clearance was also notable, with 33% and 30% of patients showing zero cell counts in the anterior chamber at Day 8 post-surgery [3] Safety Profile - Only 1.4% of patients experienced elevated intraocular pressure (IOP), significantly lower than other ophthalmic steroids, suggesting a favorable safety profile [4] - The dosing regimen is user-friendly, requiring only 1 drop twice daily for 14 days without a loading dose [4] Market Potential - The U.S. market for ophthalmic surgeries exceeds 7 million annually, presenting a substantial opportunity for BYQLOVI to capture market share in the multi-billion-dollar post-surgical care segment [2]

Group 1 - The individual known as the Michigan Value Investor (MVI) has a PhD in theoretical physics and transitioned from academia to investing, managing a small fund since 2009 [1] - MVI has developed a focused portfolio of stocks, leveraging long-standing relationships with management teams to identify investable ideas without extensive research time [1] - The investment philosophy is influenced by Warren Buffett and Charlie Munger, with a distinct preference for their teachings over those of Ben Graham [2]